Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Liabilities and Shareholders Equity (2016 - 2025)

Standard Biotools (LAB) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $539.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 20.82% to $539.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 billion, a 8.13% decrease, with the full-year FY2024 number at $612.3 million, up 89.54% from a year prior.
  • Liabilities and Shareholders Equity was $539.6 million for Q3 2025 at Standard Biotools, down from $557.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $777.7 million in Q1 2024 to a low of $271.9 million in Q1 2022.
  • A 5-year average of $448.2 million and a median of $390.3 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 109.24% in 2024, then fell 25.47% in 2025.
  • Standard Biotools' Liabilities and Shareholders Equity stood at $275.2 million in 2021, then surged by 41.82% to $390.3 million in 2022, then dropped by 17.23% to $323.1 million in 2023, then surged by 89.54% to $612.3 million in 2024, then fell by 11.87% to $539.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Liabilities and Shareholders Equity are $539.6 million (Q3 2025), $557.0 million (Q2 2025), and $579.6 million (Q1 2025).